Substance P(Neurokinin P,AbMole,M9080)是一種11氨基酸的神經(jīng)肽,屬于速激肽家族,主要通過激活神經(jīng)激肽1受體(NK1R)介導(dǎo)信號(hào)傳導(dǎo),涉及痛覺傳遞、炎癥調(diào)節(jié)和細(xì)胞間通信等細(xì)胞活動(dòng),還能調(diào)節(jié)鈣離子流量、ERK磷酸化和NF-κB活化等過程[1]。在細(xì)胞實(shí)驗(yàn)方面,Substance P(CAS No.:33507-63-0)在H9C2大鼠心肌細(xì)胞中以1-10 nM濃度預(yù)處理后,可增加細(xì)胞中磷酸化Akt(p-Akt)的水平并抑制缺氧/再氧合誘導(dǎo)的細(xì)胞凋亡[2];Substance P在皮膚肥大細(xì)胞中,可誘導(dǎo)濃度依賴性的組胺釋放,而阻斷NK1R后可抑制此效應(yīng)[3];Substance P還在SiHa宮頸癌細(xì)胞中,以濃度依賴方式促進(jìn)增殖和侵襲,并激活ERK1/2磷酸化[4];Substance P在兔成骨細(xì)胞模型中,以1 μM的濃度有效促進(jìn)成骨分化和組織修復(fù)[5];
Substance P(Neurokinin P)還可以用于神經(jīng)系統(tǒng)和疼痛相關(guān)的研究,例如在ICR小鼠神經(jīng)性疼痛模型中的研究顯示,靜脈注射Neurokinin P(1 nmol/kg)可抑制疼痛相關(guān)炎癥和疼痛因子的活性[6];Substance P在豚鼠和人類迷走神經(jīng)中,引起去極化,而
Aprepitant 可抑制上述效應(yīng)[7];Substance P還在豬急性心肌梗塞模型中,通過靜脈注射(5 nmol/kg)后提供心臟保護(hù)作用[8]。上述這些研究揭示了Substance P在細(xì)胞信號(hào)傳導(dǎo)和動(dòng)物模型中的多功能性,為理解其生物學(xué)作用提供了基礎(chǔ)。
參考文獻(xiàn)及鳴謝
[1] Spitsin, S.; Pappa, V.; Douglas, S. D. Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.
Journal of leukocyte biology 2018.
[2] Xu, Y.; Gu, Q.; Tang, J.; et al. Substance P Attenuates Hypoxia/Reoxygenation-Induced Apoptosis via the Akt Signalling Pathway and the NK1-Receptor in H9C2Cells.
Heart, lung & circulation 2018,
27 (12), 1498-1506.
[3] Hermans, M. A. W.; Schrijver, B.; van Holten-Neelen, C.; et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2018,
48 (11), 1412-1420.
[4] Wang, Y.; Yuan, S.; Ma, J.; et al. Substance P is overexpressed in cervical squamous cell carcinoma and promoted proliferation and invasion of cervical cancer cells
in vitro.
European journal of histochemistry : EJH 2023,
67 (3).
[5] Chen, J.; Liu, W.; Zhao, J.; et al. Gelatin microspheres containing calcitonin gene-related peptide or substance P repair bone defects in osteoporotic rabbits.
Biotechnology letters 2017,
39 (3), 465-472.
[6] Chung, E.; Yoon, T. G.; Kim, S.; et al. Intravenous Administration of Substance P Attenuates Mechanical Allodynia Following Nerve Injury by Regulating Neuropathic Pain-Related Factors.
Biomolecules & therapeutics 2017,
25 (3), 259-265.
[7] Smith, J. A.; Harle, A.; Dockry, R.; et al. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
American journal of respiratory and critical care medicine 2021,
203 (6), 737-745.
[8] Sim, D. S.; Kim, W.; Lee, K. H.; et al. Cardioprotective effect of substance P in a porcine model of acute myocardial infarction.
International journal of cardiology 2018,
271, 228-232.